Clinical Trials | April 08, 2026
Amgen’s TEPEZZA injection clears Phase 3 trial with high efficacy
The trial also demonstrated significant improvements across multiple secondary endpoints
The trial also demonstrated significant improvements across multiple secondary endpoints
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
Veteran HR leader comes with over two decades of experience to spearhead talent strategy, leadership development, and culture transformation
With more than two decades of experience, he brings deep expertise in sales, marketing, business transformation, and strategic leadership
Its a major breakthrough for women’s ovarian cancer care in Europe
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
The center brings together hands on technology demonstrations, application expertise, and commercial operations
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
Subscribe To Our Newsletter & Stay Updated
